EGFR and non-small cell lung carcinoma: In SATURN (Sequential Tarceva in Unresectable NSCLC) [8], however, OS improved in patients receiving maintenance erlotinib who had not progressed on first-line chemotherapy—a benefit seen both in patients with wild-type (normal) and with mutated EGFR status (p = 0.0014 and p = 0.0019, respectively, versus placebo).